Trial: Atacand cuts risk of developing diabetes

New clinical data demonstrates that AstraZeneca's Atacand reduced the risk of developing diabetes among heart failure patients. The data, published in Circulation, shows 6 percent of the group receiving Atacand developed diabetes, compared to 7.4 percent of the control group taking a placebo.

"This finding that candesartan may prevent the development of diabetes in some patients could have important future implications for the treatment of certain patient populations, such as those with hypertension, previous myocardial infarction and heart failure, in whom such treatments have already been shown to reduce major vascular events," remarked lead investigator Dr. Salim Yusuf of McMaster University.

- read this article from MarketWatch for more

ALSO: A separate trial has shown that AtraZeneca's Seroquel works to control both the manic and depressive phases of manic depression. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.